lenalidomide has been researched along with Myelomonocytic Leukemia, Chronic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R | 1 |
| Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y | 1 |
| Craddock, C | 1 |
| Burgstaller, S; Greil, R; Kuehr, T; Lang, A; Machherndl-Spandl, S; Mayrbaeurl, B; Noesslinger, T; Petzer, A; Stauder, R; Thaler, J; Valent, P | 1 |
| Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E | 1 |
| Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T | 1 |
| Buckstein, R; Chesney, A; Cheung, M; Chodirker, L; Cussen, MA; Davidson, C; Kerbel, R; Lee, CR; Lenis, M; Mamedov, A; Reis, M; Shaked, Y; Wells, RA; Zhang, L | 1 |
| Steensma, DP; Tefferi, A | 1 |
3 review(s) available for lenalidomide and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
A systematic review and meta
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic | 2014 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
3 trial(s) available for lenalidomide and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat | 2017 |
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate | 2018 |
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Topics: Aged; Aged, 80 and over; Biomarkers; Endothelial Cells; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prospective Studies; Thalidomide; Vascular Endothelial Growth Factor A | 2014 |
2 other study(ies) available for lenalidomide and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous | 2023 |
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; Vorinostat | 2017 |